iShares Neuroscience and Healthcare ETF (IBRN)
23.15
+0.28
(+1.21%)
USD |
NYSEARCA |
Apr 23, 16:00
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.47% | 0.21% | 3.440M | 404.73 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
0.06% | 61.00% | -1.144M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Small Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | iShares |
Prospectus Benchmark Index | |
NYSE FactSet Glb NeuBio&MedTech TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Greg Savage | 1.61 yrs |
Jennifer Hsui | 1.61 yrs |
Paul Whitehead | 1.61 yrs |
Performance Versus Category
As of April 23, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 23, 2024.
Basic Info
Investment Strategy | |
The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Small Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | iShares |
Prospectus Benchmark Index | |
NYSE FactSet Glb NeuBio&MedTech TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Greg Savage | 1.61 yrs |
Jennifer Hsui | 1.61 yrs |
Paul Whitehead | 1.61 yrs |